Williams Laura A sold $41K of ARDX

Williams Laura A (Chief Patient Officer) sold 10,739 shares of ARDELYX, INC. (ARDX) at $3.86 across 4 trades on 2026-08-21.

Original reporting
SEC EDGAR · Williams Laura A
Published Aug 25, 2026, 11:09 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 25, 2026, 11:21 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$ARDX
Neutral
high confidence
Mentioned
$ARDX
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ARDXNeutralLow
01

Why it matters

The sale is modest and does not materially affect Ardelyx's share structure.

02

Market read

Routine insider sale with limited trading relevance.

03

What to watch

Potential upcoming clinical trial results not yet disclosed.

Relevance 3/10Novelty 4/10Timing: filed 2026-08-25

Background

Form 4 filings disclose insider trades; investors monitor them for signals of confidence.

Company-level read

Ticker impact

$ARDXNeutralHigh confidence
Context

Chief Patient Officer Laura Williams sold 10,739 shares for $41.4K on 2026-08-21, reducing her stake to 367,456 shares.

Expected impact

No significant price impact expected.

Evidence & confidence

The sale size is small relative to market cap and insider holdings remain substantial.

Market effects

None; Ardelyx operates in a niche biotech segment with limited peer impact.

None; the transaction is company‑specific.

None; no broader market effect.

Counterpoint

If insider confidence is low, the sale could signal concerns about upcoming data.

Key entities

  • Laura Williams

    Chief Patient Officer of Ardelyx

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ARDXMed

Ardelyx (ARDX) Q3 2026 Earnings Call Transcript

Ardelyx (ARDX) reported Q3 2026 revenue of $125.5M, up 19% YoY. IBSRELA revenue grew 23% to $96.3M, while XPHOZAH revenue rose 7% to $29.2M. The company reaffirmed its full-year guidance and expects profitability in 2027. Ardelyx has $285.3M in cash and is advancing its ACCEL Phase III trial for chronic idiopathic constipation.

$ARDXLow

Ardelyx Inc (ARDX) (Q3 2026) Earnings Call Highlights: Revenue Climbs 19% as IBSRELA Shines

Ardelyx Inc (ARDX) reported a 19% revenue increase in Q3 2026, driven by its IBSRELA drug. CEO Michael Raab and CFO Sue Hohenleitner addressed prescription trends, payer negotiations, and the company's IBSRELA Pharmacy Network (IPN). They reaffirmed guidance, citing strong fundamentals and positive early indicators from a DTC campaign. The company also discussed its Phase 3 ACCEL trial for CIC and inventory dynamics for XPHOZAH.

$ARDXMedAI 8/10

What Ardelyx (ARDX) Said on Its Q3 Earnings Call

Ardelyx (ARDX) reported Q3 revenue of $29.2M for XPHOZAH, up 7% YoY. Paid prescriptions rose 22%, but demand was offset by customer buying patterns. The company maintained its full-year revenue outlook of $110M-$120M. Ardelyx also launched a direct-to-consumer ad campaign for IBSRELA, with 91% of patients expressing interest. R&D expenses increased to $25.2M, and the company reported a net loss of $700K. Ardelyx expects to reach profitability in 2027, with a gross profit margin exceeding 95%.